Abstract:Tumor angiogenesis is important in the growth and metastasis of malignant tumors. In our previous study, we demonstrated that an arginine-arginine-leucine (RRL) peptide is a tumor endothelial cell-specific binding sequence that may be used as a molecular probe for the imaging of malignant tumors in vivo. The aim of the present study was to further explore the characteristics of I-131-RRL by biodistribution tests, and to estimate the radiation dosimetry of I-131-RRL for humans using mice data. The RRL peptide was radiolabeled with I-131 by a chloramine-T (CH-T) method. The radiolabeling efficiency and radiochemical purity were then characterized in vitro. I-131-RRL was injected intravenously into B16 xenograft-bearing Kunming mice. Biodistribution analysis and in vivo imaging were performed periodically. The radiation dosimetry in humans was calculated according to the organ distribution and the standard medical internal radiation dose (MIRD) method in mice. All data were analyzed by statistical and MIRDOSE 3.1 software. The labeling efficiency of I-131-RRL reached 70.0 +/- 2.91% (n=5), and the radiochemical purity exceeded 95% following purification. In mice bearing B16 xenografts, I-131-RRL rapidly cleared from the blood and predominantly accumulated in the kidneys, the stomach and the tumor tissue. The specific uptake of I-131-RRL in the tumor increased over time and was significantly higher than that of the other organs, 24-72 h following injection (P<0.05). The ratio of tumor-to-skeletal muscle (T/SM) tissue exceeded 4.75, and the ratio of the tumor-to-blood (T/B) tissue peaked at 3.36. In the single-photon emission computed tomography (SPECT) imaging of Kunming mice bearing B16 xenografts, the tumors were clearly identifiable at 6 h, and significant uptake was evident 24-72 h following administration of I-131-RRL. The effective dose for the adult male dosimetric model was estimated to be 0.0293 mSv/MBq. Higher absorbed doses were estimated for the stomach (0.102 mGy/MBq), the small intestines (0.0699 mGy/MBq), the kidneys (0.0611 mGy/MBq) and the liver (0.055 mGy/MBq). These results highlight the potential of I-131-RRL as a ligand for the SPECT imaging of tumors. Administration of I-131-RRL led to a reasonable radiation dose burden and was safe for human use.

188Re Radiolabeling RGD Peptide and Preliminary Biodistribution Evaluation in Mice Bearing S180 Tumors

Radiolabeling and Evaluation of Re-188-Rgd As an Agent for Alpha(V)Beta(3) Receptor Expression

188Re-Labeled GX1 Dimer As a Novel Dual-Functional Probe Targeting TGM2 for Imaging and Antiangiogenic Therapy of Gastric Cancer

Radiolabeling of RGD peptide and preliminary biological evaluation in mice bearing U87MG tumors.

18F Labeled RGD‐A7R Peptide for Dual Integrin and VEGF‐targeted Tumor Imaging in Mice Bearing U87MG Tumors

Molecular Imaging and Preclinical Studies of Radiolabeled Long-Term RGD Peptides in U-87 MG Tumor-Bearing Mice

Studies on distribution and imaging of 131I-labelled RGD peptide in mice bearing tumors

131)I Labeling and Bioactivity Evaluation of a Novel RGD Dimer Targeted to Integrin Αvβ3 Receptor

Radiosynthesis and evaluation of 188 Re-c(RGDyK)-His as a novel radiotherapeutic agent for integrin α v β 3 targeting tumour

One-step Radiosynthesis of 18F-Alf-nota-rgd2 for Tumor Angiogenesis PET Imaging

Two ⁹⁰Y-Labeled Multimeric RGD Peptides RGD4 and 3PRGD2 for Integrin Targeted Radionuclide Therapy.

Evaluation of 188Re-Mag2-rgd-bombesin for Potential Prostate Cancer Therapy

Kit-like 18F-labeling of RGD-19F-arytrifluroborate in high yield and at extraordinarily high specific activity with preliminary in vivo tumor imaging.

A New Cyclic RGD Peptide Dimer for Integrin Αvβ3 Imaging.

Evaluation of Tumor Vascular Targeting Agents Labelled with 131I in Imaging of Tumor

Potential Therapeutic Radiotracers: Preparation, Biodistribution and Metabolic Characteristics of 177 Lu-labeled Cyclic RGDfK Dimer

Validation study of 131I-RRL: Assessment of biodistribution, SPECT imaging and radiation dosimetry in mice

Design and Preparation of Novel RGDyC-PEG-PAMAM Nanoprobe Targeting Integrin αvβ3 Receptor, 131I Labeling and Its Quality Control

Experimental study of 188Re labeled RGD tumor homing peptide modified recombinant human plasminogen kringle5

Preparation of 90Y-Labeled Different Cyclic RGD Peptides and Evaluation in Nude Mice Bearing Human Glioma Xenografts

Evaluation Of In-111-Labeled Cyclic Rgd Peptides: Tetrameric Not Tetravalent